China Continues to Delay Investigational Vaccine Product to Canada: Trudeau Should Consider Plan B

China Continues to Delay Investigational Vaccine Product to Canada Trudeau Should Consider Plan B

The Canadian government is showing patience and tenacity sticking with Chinese vaccine partner CanSino Biologics, despite the fact that even after a formal agreement was in place, the vaccine supply is delayed for some untold reasons.  Prime Minister Justin Trudeau recently told reporters they are still in the deal despite the delay. With a prominent Canadian site in Halifax ramped up and waiting, an uneasy situation unfolds. TrialSite suggests to Mr. Trudeau to consider a Plan B, just in case.

Good Faith Partnership?

TrialSite covered the Canadian and CanSino Biologics deal with interest. Frankly, it was a surprise given the mounting political tensions between the two countries. The founders of CanSino Biologics actually conceived of the idea while working in Canada, so the actual idea for the company is right out of Canada.

But even after negotiations and press releases with clinical trial timelines, the Chinese government failed to sign-off on releasing the drug export to Canada, reports CTV News.  By May 16, Health Canada gave the approval nod to Ad5-nCoV, and as TrialSite reported, the Canadian Center for Vaccinology (CCV) out of Dalhousie University in Halifax start...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee